Syros Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $386 |
Gross Profit | -325 | -331 | -334 | 107 |
EBITDA | -4,759 | -21,614 | -2,067 | -62,776 |
EBIT | -5,084 | -21,945 | -2,401 | -63,055 |
Net Income | -6,396 | -23,327 | -3,708 | -64,384 |
Net Change In Cash | 0 | 0 | 0 | 386 |
Free Cash Flow | -20,689 | -29,667 | -31,098 | -18,603 |
Cash | 58,275 | 78,964 | 83,523 | 139,526 |
Basic Shares | 39,269 | 39,269 | 38,978 | 29,541 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $9,936 | $14,880 | $23,488 | $15,093 |
Gross Profit | -98,217 | 11,913 | 23,488 | 15,093 |
EBITDA | -157,195 | -87,553 | -79,633 | -79,211 |
EBIT | -159,447 | -90,520 | -82,651 | -82,246 |
Net Income | -164,574 | -49,301 | -90,465 | -85,830 |
Net Change In Cash | 9,936 | 14,880 | 23,488 | 15,093 |
Cost of Revenue | 75,165 | 132,253 | ||
Free Cash Flow | -109,979 | -124,306 | -100,785 | -60,700 |
Cash | 139,526 | 167,467 | 92,302 | 173,984 |
Basic Shares | 28,325 | 12,631 | 6,253 | 4,605 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.16 |
2024-06-30 | -$0.59 |
2024-03-31 | -$0.10 |
2023-12-31 | -$2.18 |
